U.S. Markets closed

Pulmonx Corporation (LUNG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.85-0.05 (-0.31%)
At close: 04:00PM EDT
15.85 0.00 (0.00%)
After hours: 05:00PM EDT

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063
United States
650 364 0400

IndustryMedical Devices
Full Time Employees253

Key Executives

NameTitlePayExercisedYear Born
Mr. Glendon E. FrenchCEO, Pres & Director899.58kN/A1962
Mr. David A. LehmanGen. Counsel & Sec.569.14kN/A1961
Mr. Geoffrey Beran RoseChief Commercial Officer524.99kN/A1973
Dr. Derrick Sung Ph.D.Chief Financial OfficerN/AN/A1973
Mr. Sri RadhakrishnanChief Technical OfficerN/AN/AN/A
Ms. Lauren CristinaVP of Fin. & Admin. (U.S.)N/AN/AN/A
Ms. Marcee M. MaroneyVP of MarketingN/AN/A1970
Sarah HuberVP of Sales (U.S.)N/AN/AN/A
Mr. Jérôme ErathSr. VP & GM of Europe Middle-East & AfricaN/AN/AN/A
Mr. John B. McKuneVP & ControllerN/AN/A1976
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Corporate Governance

Pulmonx Corporation’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.